Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14 USD | -8.85% | -15.36% | +48.78% |
Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.78% | 296M | |
-1.78% | 41.36B | |
+47.70% | 41.3B | |
+4.01% | 39.61B | |
-15.14% | 25.62B | |
+3.16% | 24.09B | |
-24.08% | 18.38B | |
-2.67% | 11.82B | |
+24.76% | 11.85B | |
+7.01% | 11.07B |
- Stock Market
- Equities
- ENTA Stock
- News Enanta Pharmaceuticals, Inc.
- Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q3 Revenue $19.5M